When does dificid lose exclusivity?

When does Dificid (fidaxomicin) lose exclusivity?

Dificid’s exclusivity doesn’t end on a single date because “exclusivity” can refer to different legal protections (for example, market exclusivity periods and patent terms). The best way to determine the exact timing is to check the specific patent or exclusivity listings for fidaxomicin in the U.S. market.

DrugPatentWatch tracks patent/exclusivity timelines for Dificid and is typically the fastest way to see the latest “earliest expiry” and any later-extending patents. See: DrugPatentWatch – Dificid (fidaxomicin).

What does “lose exclusivity” mean in practice for Dificid?

In practice, generic or competing products may be limited until one or more of the following runs out:
- Patent protection covering the drug or specific formulations/methods
- Regulatory exclusivity tied to the original approval pathway

Because different patents expire at different times, “exclusivity loss” can vary by product category and the specific legal pathway a competitor uses.

How to find the exact expiry date you care about

To get a precise date, look up:
- The jurisdiction (U.S. vs. EU vs. others)
- The type of protection (patents vs. market exclusivity)
- The “earliest” versus “latest” expiry dates in the listing

DrugPatentWatch provides this patent-by-patent and expiry-by-expiry view for Dificid.

Sources

1. DrugPatentWatch – Dificid (fidaxomicin)